---
layout: default
title: Teplizumab
parent: Model Prediction Only (L5)
nav_order: 887
evidence_level: L5
indication_count: 10
---

# Teplizumab
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Teplizumab: From Delayed Onset of Type 1 Diabetes to Diabetic Cataract

## One-Sentence Summary

Teplizumab (brand name TZIELD in Canada) is an anti-CD3 antibody that delays the onset of type 1 diabetes.
The TxGNN model predicts it may be effective for **diabetic cataract**, but this rests on a graph-based prediction alone, with **0 clinical trials** and **0 publications** currently supporting it.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Delay of type 1 diabetes onset (taken from the pack's mechanistic notes; the Canadian license record has no indication text) |
| Predicted New Indication | Diabetic cataract |
| TxGNN Prediction Score | 98.38% |
| Evidence Level | L5 |
| Canada Market Status | ✓ Marketed |
| Number of DINs | 1 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the input. Based on known information, teplizumab is an anti-CD3 antibody that modulates T-cell-mediated autoimmune destruction of pancreatic beta cells. This is how it delays the onset of type 1 diabetes.

The only plausible link to diabetic cataract is indirect. If teplizumab delays type 1 diabetes, a patient may spend less time exposed to high blood sugar, which could lower the risk of diabetic complications such as cataract. No direct ocular mechanism is documented, and no study has shown that teplizumab's long-term glycemic benefit protects the lens. This remains a hypothesis, not a demonstrated effect.

The other nine top predictions are mostly cataract subtypes (type 2 diabetes-associated, immature, mature, senile, nuclear, cortical, craniostenosis-related and tetanic cataract) plus type 2 antithrombin deficiency. All have the same evidence level (L5). None has a plausible mechanism, and they likely reflect graph-embedding proximity rather than biology. The diabetic cataract prediction is the only one with even an indirect rationale.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Canada Market Information

| DIN | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| 2557347 | TZIELD | Not stated in the input | Not stated in the input |

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction has a high model score (98.38%) but no clinical trials, no literature and only an indirect mechanistic argument. It is at evidence level L5 (model prediction only). Teplizumab's approved use is in a young, early-stage type 1 diabetes population, which differs substantially from a typical cataract population.

**To proceed, the following is needed:**
- Mechanism of action data for teplizumab (e.g., from DrugBank), to assess any link to lens or ocular pathology
- The Health Canada package insert (warnings, contraindications), which is required before any safety screening
- The licensed indication text, dosage form and manufacturer for DIN 2557347
- A systematic literature and trial registry search for teplizumab and diabetic eye complications, including cataract
- Evidence that delaying type 1 diabetes onset translates into fewer ocular complications such as cataract
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

